CUE
Companies
NASDAQ
Cue Biopharma Inc.
Health Care
$0.66
-$0.43 (-39.86%)
Price Chart
Overview
About CUE
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
Market Cap
$72.0M
Volume
87.6K
Avg. Volume
107.9K
P/E Ratio
-1.1544828
Dividend Yield
0.00%
Employees
51.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.87
High Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
Low Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, CUE shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$72.0M
Volume87.6K
P/E Ratio-1.15
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 13, 2025Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025